Delivered Digitally

Tuesday 28th April - Friday 1st May
Panels & Keynotes
BioTrinity 2020 panel and keynote sessions will be available for viewing from Tuesday 28th April until Friday 1st May 2020.  
28-04-2020
01:00 - 01:00
add_box
James Tumbridge, an intellectual property lawyer, who has been a ministerial advisor, and holds elected office with the City of London, will take us through an update on the current status of the withdrawal of the UK with the EU, and what it means for the life sciences industry.
01:00 - 01:00
add_box
Tim Haines, Chairman and Managing Partner of Abingworth, a bioscience investment firm, will be presenting a ‘Life Science Investment Update’, where he will share his expert views on investment trends in the UK and Internationally, which research areas are receiving the most interest and some advice for R&D companies currently fundraising.  Tim will also share his thoughts on the impact that the current COVID-19 crisis will have on funding within the life sciences industry.  
01:00 - 01:00
add_box
How digital technology will transform patient care, and what new breakthroughs are on the horizon How precision medicine will continue to develop and the impact this will have on patient treatment and outcomes How technological innovations in clinical trials will impact drug development
01:00 - 01:00
add_box
This panel discussion will feature a lineup of life sciences industry leader, who will share their views on the next big life science trends that are likely to translate from the US to UK market, along with the benefits and challenges they may generate.
01:00 - 01:00
add_box
Corona virus is the most recent example of an infectious disease that we (globally) were not prepared for. It is the latest in a series of unexpected outbreaks that have occurred recently (such as Zika, MERS, SARS, Ebola). The panel will discuss how vaccines can be used as a countermeasure for these diseases, together with more familiar pandemic/epidemic suspects (such as influenza, TB, malaria, etc).
01:00 - 01:00
add_box
This session will look at the management practices of life sciences companies, in the context of creating value for shareholders.  The expert panel will be addressing a range of considerations for how a company’s management team can employ smart business decisions to increase shareholder value, whilst also reflecting on the predicted impact that the current COVID-19 crisis will have on companies in the R&D sector both in the UK & US markets in the short, medium and long-terms.
01:00 - 01:00
add_box
It is clear that big data and informatics will underpin the future success of our sector, however in the current climate organisations are struggling to translate a deluge of data into better decision making, with CEO’s working to bridge the gaps in their own capabilities.   There is a shortage of skilled talent to clean, integrate, and extract value from big data and move beyond baby steps toward AI, but where and how will this skills gap be filled in the future?
01:00 - 01:00
add_box
Antimicrobial resistance (AMR) is a severe global threat, with a UN report recently revealing that if left unchecked, it could cause as many as 10 million deaths per year by 2050.  A new report from Public Health England has found that there were an estimated 60,788 new antibiotic resistant severe infections in 2018; equivalent to 165 new antibiotic resistant infections per day.  But is overprescribing in primary care really the cause for this emerging issue? What are the other contributors, and what more can be done?  Our expert panel will consider all aspects of this global threat  
01:00 - 01:00
add_box
Cell and gene therapy represent the overlapping fields of biomedical research with similar therapeutic goals, which target DNA or RNA inside or outside the body.  The potential to directly alter human genes was first recognized nearly 50 years ago and since then, advances in scientific knowledge have led to a new and exciting era of medicine for patients, and in 2019 there are nearly 300 Cell and Gene Therapies in Development, addressing a broad Range of Diseases. The panelists in this session will provide an update on the latest successes in Cell & Gene Therapy including recent product launches, the huge potential these offer to patients, and the challenges to overcome in order to achieve maximum global impact, along with: Overview on recent & upcoming commercial product launches What are the current manufacturing challenges in Cell & Gene Therapy to repeat the success of the mAb story? How far are we with respect to global standardization to address comparability? Overcoming manufacturing challenges to make treatments more affordable Which new technologies such as CRISPR/ RNA editing /Exosomes are emerging on the horizons?
01:00 - 01:00
add_box
Medical and clinical diagnostics is the practice of detecting, identifying and monitoring a disease or medical disorder, and is a research space undergoing a huge and exciting technological evolution, with new diagnostic tools and devices regularly coming to market.   The panel will look at the potential impact that the most recent advances will have on the diagnosis and onward treatment of patients with a broad range of conditions.
01:00 - 01:00
add_box
Since 1992, there have been nearly 25 consecutive years of decline in overall incidence and mortality rates for all types of cancer. In addition, the number of people living 5 years or more after a cancer diagnosis is projected to increase 31% by 2026, representing an increase of more than four million survivors in less than a decade.   New thinking, new research and new treatments are constantly evolving in Oncology, and this panel will bring together a group of experts from all corners of the industry to look at recent successes, and new launches on the horizon that have the potential to positively change the diagnosis and treatment options for millions of cancer patients around the world.
01:00 - 01:00
add_box
Almost one in eight people died from dementia and Alzheimer’s disease in 2018, with the proportion increasing for the fourth consecutive year – up from 12.7% in 2017 to 12.8% in 2018.  The number of people living with dementia in the UK is expected to rise to 1 million by 2021 and the increase in the numbers was a result of people living longer, surviving other illnesses and of the syndrome being better understood by doctors.
Processing. Please wait.
Loading...